Lenz Therapeutics' eye disease drugs meet main goal of late-stage study (updated)
03/04/2024 12:27
(Adds details in paragraphs 2-4)
April 3 (Reuters) - Lenz Therapeutics LENZ.O said on
Wednesday its experimental drugs to treat loss of near vision
met the main goal of a late-stage study, sending its shares up
nearly 23% before the bell.
The company said it has identified one of the drugs, LNZ100,
as its lead product candidate as it showed statistically
significant improvement in patients' ability to see details at a
distance of 20 feet at three hours post-treatment.
The other drug, LNZ101, also showed similar results but did
not show superiority to LNZ100, the San Diego, California-based
company said.
Lenz plans to submit a marketing application for LNZ100 in
the United States in mid-2024.
(Reporting by Sneha S K in Bengaluru; Editing by Shilpi
Majumdar)
((Sneha.SK@thomsonreuters.com;))